GLP-1 strength training

Bone health on GLP-1 medications: why strength training matters beyond the scale

Rapid weight loss from GLP-1 medications can reduce bone mineral density even as body weight improves. Resistance training is the primary mechanical stimulus that counteracts this — and DEXA can track both outcomes.

5 min read · by · educational content, not medical advice

How weight loss affects bone density

  • Bone is a mechanically sensitive tissue. It remodels in response to the loads placed on it — a process governed by bone-forming osteoblasts and bone-resorbing osteoclasts. When mechanical load decreases, bone resorption outpaces formation and density declines.
  • Weight loss reduces mechanical loading on the skeleton in two ways: lower total body mass means less gravitational load during daily movement, and adipose tissue itself contributes modest mechanical and hormonal support to bone.
  • Clinical trial data from GLP-1 medications including semaglutide and tirzepatide have shown reductions in bone mineral density at the hip of approximately 1–2% over 68 weeks. While this may seem small, the cumulative effect over years of GLP-1 use — and the fact that many GLP-1 users are already in their 40s or 50s — makes this clinically relevant.
  • The concern is highest in postmenopausal women and older men who are already at elevated fracture risk. Adults in these groups should discuss bone monitoring with their prescriber, particularly with long-term GLP-1 use.

Why GLP-1 specifically and what the evidence shows

  • GLP-1 receptors are expressed on bone cells, which initially raised hopes that GLP-1 medications might have a protective effect on bone. Clinical trial data has been more mixed. Weight loss appears to outweigh any direct receptor-mediated bone benefit in most studies.
  • The SURMOUNT-1 trial of tirzepatide showed statistically significant reductions in bone mineral density at the total hip at 68 weeks. Similar signals have been reported with semaglutide in the STEP trials, though effects vary by site and duration.
  • Crucially, the bone density loss in these trials occurred in the absence of structured resistance training programs. This gap is a design feature of the trials, not a fundamental limit of what is possible with the medication.
  • Several smaller studies examining exercise combined with GLP-1 use have shown that resistance training substantially attenuates bone density loss during the same weight-loss period — consistent with the established literature on exercise and bone during caloric restriction.

What resistance training does for bone

  • Resistance training is the most evidence-supported non-pharmacological intervention for maintaining or improving bone mineral density in adults. The mechanism is mechanical loading — bones that bear progressively heavier loads adapt by increasing density and structural integrity (Wolff's Law).
  • The most osteogenic exercises involve heavy axial loading: squats, deadlifts, trap bar deadlifts, farmer's carries, and overhead pressing. These exercises create compressive and torsional forces at the hip and spine — the sites most vulnerable to bone loss.
  • Studies in postmenopausal women — the highest-risk population for osteoporosis — consistently show that progressive resistance training maintains or modestly improves bone mineral density at the hip and lumbar spine, even during periods of caloric restriction.
  • Aerobic exercise contributes less to bone density than resistance training. Walking and low-impact cardio are beneficial for general health but provide insufficient mechanical stimulus to meaningfully stimulate bone formation at the hip and spine.

Nutrition factors: protein and calcium

  • Adequate protein intake supports bone health as well as muscle retention. Bone is approximately 50% protein by volume — collagen provides the structural scaffold that mineral deposits adhere to. Low protein diets are associated with lower bone mineral density independent of calcium intake.
  • Calcium intake of 1000–1200 mg per day (the range recommended for most adults by Health Canada and similar bodies) supports bone maintenance during weight loss. Dairy products, fortified plant milks, leafy greens, and calcium supplements are practical sources.
  • Vitamin D is required for calcium absorption. Adults in northern climates — including most of Canada — are frequently deficient, particularly in winter. Supplementation of 800–2000 IU per day is a reasonable precaution, particularly for adults on GLP-1 medications undergoing bone-relevant weight loss.
  • GLP-1 medications reduce total food intake, which can reduce calcium and vitamin D intake alongside protein. Being intentional about these nutrients during a GLP-1 phase requires slightly more attention than in normal eating conditions.

How DEXA fits in

  • DEXA scans measure bone mineral density (BMD) and bone mineral content (BMC) at the hip, lumbar spine, and total body — at the same time as lean and fat mass. This makes a single DEXA scan informative for both body composition and bone health.
  • Baseline DEXA before or early in a GLP-1 phase establishes a BMD reference point. A follow-up scan after 6–12 months can identify whether bone density is stable, improving with resistance training, or declining in ways that warrant clinical discussion.
  • T-scores and Z-scores are the standard reporting format for bone density. T-score is compared to peak young adult bone density; Z-score is compared to age-matched norms. Interpretation of clinical significance — especially values in the osteopenic range — belongs with your physician or the clinician who ordered the scan.
  • DEXA provides a uniquely integrated data picture for adults on long-term GLP-1 therapy: body composition change (lean mass, fat mass, visceral fat) and bone health in a single low-radiation scan.